Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double‐blind, placebo‐controlled study

Finer, N., Bloom, S. R., Frost, G. S., Banks, L. M., Griffiths, J. · 2000 · Diabetes, Obesity and Metabolism

Abstract

Summary: Aims : To assess the efficacy and tolerability of sibutramine 15 mg once daily as a weight reduction agent in overweight and obese patients (body mass index (b.m.i.) > 26 kg/m 2 ) with type 2 diabetes when given with a customised, reduced‐calorie diet, and to evaluate the influence of weight loss on diabetic control. Methods : Randomised, placebo‐controlled, double‐blind, parallel‐group, 12‐week study conducted at two hospital‐based obesity/diabetes clinics. Patients were men and women aged 30–65 years, with b.m.i. > 26 kg/m 2 and ≤ 35 kg/m 2 and treated or untreated type 2 diabetes diagnosed ≥ 6 months previously. Each patient was given sibutramine 15 mg or placebo once daily and advised to follow a customised diet of 500 kcal/day less than the individual's energy needs. The principal measure of efficacy was change in body weight (b.w.). Additional efficacy measurements were changes in b.m.i., body composition as measured by dual‐energy X‐ray absorptiometry, and change in waist and hip measurements. Changes in diabetic control were assessed by blood glucose levels fasting and after a standard test meal, fasting insulin level, and glycosylated haemoglobin level. Adverse events (AEs) were monitored at each visit, and routine laboratory safety tests were done at 4‐week intervals. Results : Ninety‐one patients were randomised into the study, 44 to placebo and 47 to sibutramine 15 mg once daily. Eighty‐three patients (91%) completed the study, 40 (91%) on placebo and 43 (91%) on sibutramine. Mean weight reduction from baseline was statistically significantly greater with sibutramine than with placebo at every measurement and at the end of the study (2.4 vs. 0.1 kg at week 12; p < 0.001; intent‐to‐treat). The proportion of patients who lost > 5% of their baseline b.w. was 19% in the sibutramine group and 0% in the placebo group (p < 0.001; 95% confidence interval: 9, 30). Patients receiving sibutramine lost significantly more fat mass compared with those receiving placebo, as a percentage (1.0% vs. 0.1%; p < 0.05) and in absolute terms (1.8 vs. 0.2 kg, p < 0.001). Loss of lean mass was not significantly different between the groups. Mean peak blood glucose concentration after a standard test meal decreased by 1.1 mmol/l in the sibutramine treatment group but increased by 0.5 mmol/l in the placebo group (p = 0.04; difference in means, 1.6, 95% confidence interval: −3.3, −0.1). Mean fasting blood glucose decreased by 0.3 mmol/l with sibutramine and increased by 1.4 mmol/l with placebo. Mean glycosylated haemoglobin levels decreased by 0.3% units with sibutramine treatment, and were unchanged with placebo. However, more sibutramine‐treated patients (33%) than placebo‐treated patients (5%) achieved decreases in glycosylated haemoglobin of 1% unit or more (p < 0.05). Sibutramine 15 mg was safe and well tolerated, and AEs were mostly mild or moderate in severity. No significant differences were found between treatment groups in blood pressure. No clinically significant conduction or rhythm abnormalities were observed on ECG. Conclusions : Sibutramine 15 mg once daily with a customised, reduced‐calorie diet significantly reduced weight compared with placebo in overweight and obese patients (b.m.i. > 26 kg/m 2 ) with type 2 diabetes. Sibutramine was well tolerated, and significant improvement in diabetic control was seen in conjunction with weight reduction on sibutramine treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1463-1326.2000.00071.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 171

Metadata

Authors
Finer, N., Bloom, S. R., Frost, G. S., Banks, L. M., & Griffiths, J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2000-03
Volume
2
Issue
2
Pages
105-112
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2107706963
Cited by
171
References
2
FWCI
9.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double‐blind, placebo‐controlled study. https://app.cochat.ai/papers/10.1046/j.1463-1326.2000.00071.x
The paper
Finer, N., Bloom, S. R., Frost, G. S., Banks, L. M., & Griffiths, J. (2000). Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double‐blind, placebo‐controlled study. Diabetes, Obesity and Metabolism. https://doi.org/10.1046/j.1463-1326.2000.00071.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.